<DOC>
	<DOCNO>NCT01205230</DOCNO>
	<brief_summary>The purpose study determine dose ketoconazole ( Nizoral ) esomeprazole ( Nexium ) affect pharmacokinetics oral pazopanib . The study also test safety pazopanib administer ketoconazole esomeprazole .</brief_summary>
	<brief_title>VEG113971 : An Open-Label Study Effects Ketoconazole Esomeprazole Pazopanib PK</brief_title>
	<detailed_description>The study 2-arm , open-label , repeat-dose , single sequence , crossover , study design evaluate effect ketoconazole ( Arm A ) esomeprazole ( Arm B ) pharmacokinetics ( PK ) oral pazopanib subject solid tumor malignancy . This study compare PK parameter oral pazopanib metabolite concentration give alone co-administered either ketoconazole ( Arm A ) esomeprazole ( Arm B ) . Safety assessment ( physical examination , vital sign , 12-lead electrocardiogram , Eastern Cooperative Oncology Group performance status , clinical laboratory assessment , monitor adverse event ) also evaluate study .</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Signed , write informed consent 18 year age legal age consent great 18 year time sign consent Histologically confirm diagnosis refractory relapse advanced solid tumor malignancy standard therapy OR standard therapy OR subject opts receive standard therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate baseline organ function Subjects may transfusion within 7 day screen assessment . Subjects receive anticoagulant therapy eligible INR stable within protocol recommend range . Male OR Female nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : hysterectomy , bilateral oophorectomy ( ovariectomy ) , bilateral tubal ligation , postmenopausal OR Nonpregnant Female childbearing potential , include female negative serum pregnancy test within 14 day prior first dose study treatment , agree use acceptable contraceptive method , use consistently accordance product label instruction study physician . OR Female , lactating , agree stop nursing prior first dose 14 day last dose study drug Able swallow retain orally administer medication History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 2 month prior first dose study drug Clinically significant GI abnormality may increase risk GI bleed include , limited : active peptic ulcer disease , know intraluminal metastatic lesion/s risk bleed inflammatory bowel disease ( e.g. , ulcerative colitis , Crohn 's disease ) , GI condition increase risk perforation , history abdominal fistula , GI perforation , intra abdominal abscess within 28 day prior begin study treatment . Clinically significant GI abnormality may affect absorption investigational product include , limited : malabsorption syndrome , major resection stomach small bowel . Presence uncontrolled infection . Corrected QT interval ( QTc ) &gt; 480 msec . History one follow cardiovascular condition within past 6 month : cardiac angioplasty stenting , myocardial infarction , unstable angina , coronary artery bypass graft surgery , symptomatic peripheral vascular disease , Class III IV congestive heart failure , define New York Heart Association ( NYHA ) . Poorly controlled hypertension Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . History cerebrovascular accident include transient ischemic attack , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major ) . Evidence active bleeding bleed diathesis . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel . Hemoptysis excess 2.5 mL ( onehalf teaspoon ) within 8 week first dose study drug . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Treatment follow anticancer therapy : radiation therapy , surgery tumor embolization within 14 day prior first dose pazopanib OR chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day 5 halflives drug ( whichever longer ) prior first dose pazopanib . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 ( grade NCICTCAE , version 4.0 ) , time enrollment and/or progress severity , except alopecia well stable ( &gt; 4 week ) â‰¤Grade 2 neuropathy rash . Unable unwilling discontinue use protocolprohibited medication least 14 day 5 half life drug ( whichever longer ) prior first dose study drug duration study . Use HRT prior study enrollment due potential inhibition cytochrome P450 enzymes metabolize estrogen progestin ( Arm A female subject ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Esomeprazole</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>Safety</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>